Ono Pharmaceutical Co. (OTCMKTS:OPHLF) Sees Large Growth in Short Interest

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 1,994,790 shares, an increase of 98.7% from the May 31st total of 1,003,767 shares. Based on an average daily trading volume, of 3 shares, the days-to-cover ratio is currently 664,930.0 days. Currently, 0.4% of the company’s shares are short sold.

Ono Pharmaceutical Stock Performance

OPHLF opened at $13.50 on Friday. The firm has a market capitalization of $6.34 billion, a P/E ratio of 13.64 and a beta of 0.34. Ono Pharmaceutical has a 12-month low of $9.20 and a 12-month high of $18.67. The stock’s 50 day moving average price is $14.36 and its two-hundred day moving average price is $14.58. The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10.

Analysts Set New Price Targets

Separately, Zacks Research raised Ono Pharmaceutical to a “hold” rating in a research report on Friday, April 17th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold”.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.